• About us
• Contact

Advertisement

Organisation › Details

Immunic (Group)

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, vidofludimus calcium (IMU-838), a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn’s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor ROR?/ROR?t, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. *

 

	Start	2019-04-12 renamed
	Industry	immuno modulatory compound (IMO)
	Industry 2	MS DRUGS
	Person	Vitt, Daniel (Immunic 201701– CEO before 4SC 1997–201612 CSO + Co-Founder before Univ Würzburg)
	Person 2	Whaley, Glenn (Immunic 202203– promoted to CFO joined 2019 before Pernix Therapeutics + Alvogen)
	Region	Gräfelfing
	Country	Germany
	Street	21 Lochhamer Schlag
	City	82166 Gräfelfing
	Tel	+49-89-250079460
		Address record changed: 2024-01-05
Basic data	Employees	C: 51 to 100 (2023-01-01)
	Currency	USD
	Profit	-120,407,000 (2022-12-31)
	Cash	106,745,000 (2022-12-31)
		* Document for »About Section«: Immunic, Inc.. (3/16/22). "Press Release: Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer". New York, NY.
		Record changed: 2023-12-30

Advertisement

More documents for Immunic (Group)

• [1] Immunic, Inc.. (1/5/24). "Press Release: Immunic, Inc. Announces Private Placement of up to $240 Million". New York, NY....
• [2] Immunic, Inc.. (11/2/23). "Press Release: Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts". New York, NY....
• [3] Immunic, Inc.. (10/10/22). "Press Release: Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing". New York, NY....
• [4] Immunic, Inc.. (7/6/22). "Press Release: Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén". New York, NY....
• [5] Immunic, Inc.. (6/2/22). "Press Release: Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update". New York, NY....
• [6] Immunic, Inc.. (3/16/22). "Press Release: Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer". New York, NY....
• [7] Immunic, Inc.. (10/14/21). "Press Release: Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer". New York, NY....
• [8] Immunic, Inc.. (7/19/21). "Press Release: Immunic, Inc. Announces Closing of $45.0 Million Public Offering". New York, NY....
• [9] Immunic, Inc.. (3/31/21). "Press Release: Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838". New York, NY & Planegg-Martinsried....
• [10] Immunic, Inc.. (2/26/21). "Press Release: Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity". New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.